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Local staging of rectal cancer: the current role
of MRI
Abstract With the advent of power-
ful gradient coil systems and high-
resolution surface coils, magnetic
resonance imaging (MRI) has recently
extended its role in the staging of
rectal cancer. MRI is superior to
endorectal ultrasound, the most
widely used staging modality in pa-
tients with rectal tumors, in that it
visualizes not only the intestinal wall
but also the surrounding pelvic anat-
omy. The crucial advantage of MRI is
not that it enables exact T-staging but
precise evaluation of the topographic
relationship of a tumor to the meso-
rectal fascia. This fascia is the most
important anatomic landmark for the
feasibility of total mesorectal excision,
which has evolved into the standard
operative procedure for the resection
of cancer located in the middle or
lower third of the rectum. MRI is
currently the only imaging modality
that is highly accurate in predicting
whether or not it is likely that a tumor-
free margin can be achieved and thus
provides important information for
planning of an effective therapeutic
strategy, especially in patients with
advanced rectal cancer.
Keywords Rectal cancer . Staging .
MRI . Rectal carcinoma
Introduction
Colorectal cancer is the third most common cancer
worldwide [1, 2]. In the United States, about 145,000
new cases and 56,000 deaths were estimated for 2005 [1].
In recent years, mortality rates have decreased due to major
changes in therapeutic management, in particular the
standardization of the operative procedure and the
introduction of adjuvant and neoadjuvant therapy [1].
Colorectal cancer primarily develops from adenomatous
polyps over a period of 10–15 years, known as the
adenoma-carcinoma sequence [3]. The incidence of polyps
increases with age and the risk of malignant transformation
of a polyp markedly increases with its diameter. The rate of
malignant transformation is about 1% for polyps less than
1 cm in diameter, but 10% for larger ones [4, 5]. Around
40–50% of colorectal cancers are located in the rectum.
Rectal cancer is defined as a tumor whose aboral margin
measured with the rigid rectoscope is 16 cm or less from
the anocutaneous line. This distance serves to classify
rectal cancer into tumors of the upper third (12–16 cm), the
middle third (6–12 cm), and the lower third (<6 cm) [6]
according to the UICC.
The mesorectal fascia is an important anatomic land-
mark for the diagnostic evaluation of local tumor extent [7]
(Fig. 1b). The fascia is a connective tissue sheath that
encloses the rectum and the perirectal fatty tissue,
including lymph nodes and lymphatic vessels down to
the pelvic floor and acts as a natural barrier for tumor
spread. The ability to visualize the mesorectal fascia on CT
images has been described more than 20 years ago [8].
MRI currently is the most advanced staging modality able
to depict the fascia and its relation to the tumor margins
precisely.The following article will give an overview of the
staging modalities currently used in rectal cancer staging,
with an emphasis on the role of MRI and its significance
for planning an effective therapeutical strategy for the
individual patient.
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Surgery
The anatomic position of the rectum in the true pelvis and
its vicinity to adjacent anatomy, in particular the sphincter
muscles, poses a challenge for the surgeon regardless of the
surgical technique used. Surgical treatment of rectal cancer
is a difficult balancing act between minimizing the risk of
local recurrence and the preservation of anorectal and
genitourinary function.
Total mesorectal excision (TME)
The introduction of standardized TME [9] has considerably
improved prognosis in patients with cancer located in the
middle or lower third of the rectum. Using this operative
technique, the rectum is resected together with all
surrounding lymphatic pathways, lymph nodes, mesorectal
fatty tissue, and the mesorectal fascia while the parietal
pelvis fascia and the pelvic splanchnic nerves (nervi
erigentes) are spared. The widespread introduction of TME
has markedly reduced the rate of non-continence-preserv-
ing abdominoperineal operations for rectal cancer.
Local excision is an option in patients with very small,
well to moderately differentiated tumors that are confined
to the mucosa and submucosa [10]. Techniques used for
local excision are transanal surgical tumor removal and
endoscopic microsurgical tumor ablation. Only a few
patients are candidates for local excision (about 5%) and
these must be selected with great care.
Circumferential resection margin (CRM) and local
recurrence
The local recurrence rate after surgery performed with
curative intent ranges between 3% and32% [11]. For TME,
some studies report local recurrence rates that are markedly
below 10% [12–14]. Lateral circumferential tumor extent is
a much more important prognostic factor for local recur-
rence than longitudinal tumor extent. Incomplete resection
of the lateral tumor margins is now considered the most
important cause of local recurrence [15–17]. In a study by
Quirke et al. [15], 83% of the patients with a positive CRM
had local tumor recurrence. Hence, the topographic
relationship of the tumor to the mesorectal fascia that
serves as a natural barrier and anatomic landmark for TME
is the most important criterion in local tumor staging for
therapeutic decision making.
Adjuvant/neoadjuvant therapy
The aims of adjuvant or neoadjuvant therapy are to enable
or facilitate total tumor resection even in advanced disease,
to prevent local tumor recurrence, and to minimize the risk
of distant metastases. Adjuvant or neoadjuvant therapy
leads to downstaging of the tumor [18, 19] in terms of its T
and N stages, and 20% of patients even show complete
tumor regression (sterilization) [20].
The timing of adjuvant or neoadjuvant therapy is still a
matter of debate. Based on the results of two large studies
[21, 22], preoperative radiotherapy alone or combined
radiochemotherapy is the preferred option for tumors of the
middle or lower rectum in Europe. One of these studies,
performed in Scandinavia [21], showed that a short cycle of
preoperative radiotherapy reduces the local recurrence rate
from 27% to 11%. The second study showed that even
patients who underwent TME, which already has a lower
recurrence rate than other operative approaches, benefit
from preoperative radiotherapy [22]. Preoperative irradia-
tion significantly reduced local recurrence compared to the
group treated by TME only. In the United States, adjuvant
therapy consisting of combined postoperative radioche-
motherapy is favored for patients with T3 and/or N1
tumors. [23].
Fig. 1 a Axial T2-weighted
FSE (TSE) sequence of the
pelvis depicting the layers of the
rectal wall. The mucosa and
submucosa can be visualized as
a relatively hyperintense band
(arrows). The hypointense line
(arrowheads) represents the
muscularis propria. b Axial T2-
weighted FSE (TSE) sequence.
The mesorectal fascia can be
visualized as a thin line (arrow-
heads), enveloping the meso-
rectal compartment, containing
the rectum, mesorectal fat, blood
vessels, lymphatic vessels and
nodes
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Tumor staging is crucial for the prognosis and planning of
therapy in the individual patient and aims at precisely
determining the extent of the tumor as a basis for deciding
whether surgery alone or surgery in combination with
neoadjuvant therapy is the most suitable strategy. Of
course, it is of great importance to avoid overtreatment or
undertreatment of the patient. To reach a high level of
accuracy in rectal cancer staging and to develop an
adequate individual strategy for therapy, it is indispensable
to establish a multidisciplinary team [24]. Rectal cancer
staging is now mostly based on the TNM andUICC staging
systems [6] (Tables 1, 2), which have largely replaced the
older Dukes classification. The most important anatomic
structure on which staging is based using these staging
systems is the lamina muscularis propria. While T1 rectal
carcinomas are confined to the mucosa and submucosa, T2
tumors invade the muscularis propria (Figs. 2a–c and 3). A
T3 cancer is defined as a tumor extending beyond the
lamina muscularis propria (Figs. 4, 5). However, none of
the staging systems takes into account the fact that the T3
tumors are a very heterogeneous group, comprising tumors
that just barely extend beyond the lamina muscularis
propria as well as tumors that extend to or invade the
mesorectal fascia (Figs. 4, 5) without further subclassifica-
tion. The therapeutically important topographic relation-
ship of the lateral tumor margins to the mesorectal fascia is
not taken into consideration. An adequate, state-of-the-art
staging classification should be able to precisely determine
this relationship and to predict whether a tumor-free CRM
is likely to be achieved or not. In this way one would be
able to differentiate patients with minimal mesorectal
infiltration in whom neoadjuvant therapy is not mandatory
from patients who would definitely benefit from neoadju-
vant therapy because the mesorectal fascia is infiltrated or
at risk. T4 rectal cancers are defined as tumors, that reach
the peritoneal surface or adjacent organs (Figs. 6a,b, 7, 8).
Staging modalities
Endorectal ultrasound (EUS)
EUS is the oldest and most widely used imaging technique
for evaluating the local extent of rectal cancer. EUS depicts
the anatomic layers of the rectal wall with a high degree of
accuracy and thus enables precise determination of the
tumor extent in relation to the different wall layers.
Reported accuracy rates of transrectal ultrasound in
assessing the T stage are in the range of 69–97% [25–
35]. EUS is most suitable for evaluating early rectal cancer
while it is limited in assessing more advanced tumors.
Although EUS allows the identification of transmural
tumor growth, exact determination of the circumferential
tumor spread and—even more important—depiction of the
relation between the edges of the tumor and the mesorectal
fascia is often not possible due to the limited scan depth
caused by the high frequencies used. Moreover, the
accuracy varies widely with the examiner’s experience
[28, 36].
Computed tomography (CT)
Most older studies report rather low accuracy rates of only
52–70% [32, 37–41] for T-staging by CT. It is remarkable
that accuracy levels reported in studies including less
advanced tumors were considerably lower compared with
those including only advanced tumor stages. The poor
accuracy of CT in the staging of superficial tumors is
mainly attributable to the fact that these studies used
conventional CT protocols with low spatial and contrast
resolution. The accuracy has since been improved by the
advent of the multislice technique (MSCT). In a study of 92
patients by Kulinna et al. [42], T-staging using MSCT was
found to have an accuracy of 86%, while Filippone et al.
[43] found an accuracy of 83% in a study of 41 patients. If
one takes into account that four-row CTscanners were used
in these studies, it is evident that further improvement is to
be expected from state-of-the-art CTscanners with up to 64
detector rows that are already in use today. Hence, the role
Table 1 TNM classification for colorectal cancer
Type Description
T1 Tumor involves submucosa
T2 Tumor involves muscularis propria
T3 Tumor beyond muscularis propria
T4 Tumor reaches peritoneal surface or invades adjacent organ
N0 No involved nodes
N1 Up to three perirectal/colic nodes
N2 Four or more perirectal/colic nodes
Table 2 UICC staging of rectal carcinoma
Stage Description
Stage 0 Tis N0 M0
Stage I T1 N0 M0
T2 N0 M0
Stage IIA T3 N0 M0
BT 4 N 0 M 0
Stage IIIA T1, T2 N1 M0
B T3, T4 N1 M0
C Every T N2 M0
Stage IV Every T Every N M1
381of MSCT in the local staging of rectal cancer remains to be
defined. CT is superior to both EUS and MRI in that the
scan typically covers the entire abdomen and pelvis and
thus also allows evaluation of the liver, the most important
target organ of hematogenic metastatic spread of rectal
cancer.
MRI
It is undisputed that MRI is the imaging modality with the
highest soft-tissue contrast. This is why MRI is also used
for staging rectal cancer. However, initial results with MRI
were disappointing, with accuracies in T-staging reported
in older studies ranging between 58 and 74% [39, 44–46].
These rather poor results are primarily due to the poor
spatial resolution achieved with the whole-body coil
systems used in these studies. When endorectal coils are
used, MRI has similar accuracies as EUS [31, 47–49]. MRI
using endorectal coil systems is comparable to EUS in that
it allows highly accurate differentiation of the layers of the
intestinal wall. However, endorectal coils also have a
number of disadvantages. As with EUS, the field of view
(FOV) is rather small and only allows adequate evaluation
of early stages of rectal cancer because the evaluation of
surrounding pelvic anatomy is limited. In patients with
advanced tumors, insertion of the coil system may be
impossible or is very painful. Another disadvantage is the
high cost of endorectal coils, which are usually disposable.
The advent of powerful gradient systems and, above all,
the development of high-resolution phased array surface
coil systems in recent years brought the breakthrough in the
staging of rectal cancer by MRI. The use of these phased-
array surface coils combines a very high spatial resolution
with a large FOV that allows not only detailed evaluation
of the intestinal wall but also depicts surrounding anatomy
including the mesorectal fascia.
Imaging technique
Rectal cancer staging by MRI is rather fast and
straightforward. No special patient preparation is required.
Some authors recommend administration of a positive or
negative enteral contrast medium, but this seems not to be
necessary as suggested by current data in the literature. A
Fig. 3 Paraxial T2-weighted FSE (TSE) sequence. Tumor of the
rectal wall. Fibrous strands into the mesorectum represent desmo-
plastic reaction (arrow). A differention between desmoplastic
reaction and tumor infiltration of the mesorectum can be difficult
Fig. 2 a Paraxial T2-weighted FSE (TSE) sequence. T1/2 rectal
cancer. The relatively hyperintense intraluminal tumor (arrowhead)
is confined to the rectal wall. Tumor invasion of the mesorectum is
not visible. b Paraxial 3D-MPR and c intraluminal (virtual
endoscopy) CT reconstuctions after rectal insufflation of CO2
showing the same tumor as a
382study published only recently even indicated that rectal
distension significantly reduces the distance between the
rectal wall and the mesorectal fascia and that this might
impact on the ability of MRI to predict accurately the
distance between the tumor and the potential resection
margin [50].
At our department, we administer a spasmolytic agent
(butylscopolamine) at a dose of 20–40 mg to prevent
artifacts caused by peristalsis of the small intestine and to
distend the sigmoid and rectum. The agent has a short half-
life and is therefore injected intramuscularly immediately
before MRI.
For efficient planning of the pulse sequences to be
employed, the radiologist performing the examination
should beforehand obtain information about the approxi-
mate tumor localization (distance from anocutaneous line
in cm) from the referring surgeon and ask the patient about
any previous surgery or diseases of the pelvic organs.
The patient is positioned comfortably on the back and a
phased-array surface coil is placed on the pelvis in such a
way that the lower edge of the coil comes to lie well below
the pubic bone. The coil is kept in place with belts and the
patient is then advanced head-first into the bore of the
magnet.
Following the usual localizer scans, a sagittal T2-
weighted half-Fourier single shot turbo spin-echo (SSFSE,
HASTE) sequence with a large field of view (FOV) should
be acquired to obtain an overview and for planning of the
subsequent sequences (e.g. TR ∞, TE 62 ms, slice thickness
5 mm, FOV 255×340 mm, matrix size 116×256, voxel size
2.2×1.3×5 mm). Precise tumor localization is then achieved
with an axial T2-weighted fast spin-echo (FSE) or turbo
spin-echo (TSE) sequence with a large FOV and a slice
thickness of 5 mm (e.g. TR 4,170 ms, TE 98 ms, FOV
300×220 mm, matrix 282×512, voxel size 0.8×0.6×5 mm).
At the core of the examination is a high-resolution T2-
weighted TSE sequence with a small FOV and a slice
thickness of 3 mm (e.g. TR 3,570 ms, TE 68 ms, FOV
180×180 mm, matrix 179×256, voxel size 1.0×0.7×3 mm).
It is mandatory to place the slices perpendicular to the
longitudinal axis of the tumor or the intestinal lumen in
the vicinity of the tumor. With this sequence, it is possible
to precisely evaluate the tumor and its relationship to the
intestinal wall, mesorectal fascia, the pelvic organs, and
possibly also to the peritoneal fold. Moreover, mesorectal
lymph nodes in the immediate vicinity of the tumor can be
evaluated. For visualization of more distant lymph nodes in
our institution a T1 to proton-density-weighted two-
dimensional (2D) TSE sequence with a short echo train
length (e.g. 3 or 5) in axial orientation (e.g. TR 1,980 ms,
TE 10 ms, slice thickness 5 mm, FOV 300×225 mm, matrix
219×512, voxel size 1× 0.6×5 mm), which covers the entire
area up to the aortic bifurcation is used. Alternatively, a T1-
weighted 3D gradient-echo sequence can be used for this
purpose, allowing for the reconstruction of thinner slices.
Possible infiltration of the anal sphincter muscles in patients
with low tumors is evaluated using a coronal T2-weighted
FSE (TSE) sequence (e.g. TR 3,570 ms, TE 68 ms, FOV
180×180, matrix 179×256, voxel size 1.0×0.7×3 mm)
positioned parallel to the longitudinal axis of the anal canal.
Current data in the literature suggests that intravenous
contrast medium administration does not improve staging
of rectal tumors by MRI [51, 52].
Fig. 5 Paraxial T2-weighted FSE (TSE) sequence. A T3 rectal
cancer widely invades the mesorectum. A tumor deposit (arrow)i s
located directly adjacent to the mesorectal fascia (arrowhead). A
tumor-free resection margin cannot be predicted
Fig. 4 Paraxial T2 weighted FSE (TSE) sequence. A T3 rectal
cancer breached through the muscularis propria (arrow) and invades
the mesorectum. The tumor does not reach the mesorectal fascia
(arrowheads). A tumor-free CRM can be expected
383Since differentiation with the T2-weighted sequences is
based on the contrast between the high-signal-intensity
mesorectal fatty tissue and the rather low signal intensity of
the tumor, spectral fat suppression techniques are not
needed. The duration of the MRI protocol as just outlined is
about 25–30 min, including planning.
T-staging
Although the introduction of phased-array coil systems has
improved the accuracy of MRI in staging rectal cancer,
even more recent studies report accuracies of only 67–86 %
for T-staging [53–56]. These disappointing results are
primarily due to the poor differentiation of T1/2 cancer
from so-called borderline T3 cancer, where it is often not
possible to distinguish true mesorectal tumor invasion from
desmoplastic reactions (Fig. 3)[ 49, 54, 57]. Desmoplastic
reactions are reactive tissue alterations which often occur in
the immediate surrounding of tumors, most frequently
resulting in fibrotic extensions that may contain tumor cells
or not. The failure to differentiate between desmoplastic
reactions and tumor growth is not specific to MRI but is
also a well-known problem in rectal cancer staging with
EUS [27]. Clinically and therapeutically, however, this
differentiation is of minor importance. As already men-
tioned, it is much more important to precisely describe the
Fig. 8 Recurrent rectal cancer. Paraxial T1-weighted SE sequence
with fat suppression after i.v. apllication of gadopentetate-dimelglu-
mine at a dosage of 0.2 mmol/kg body weight. The large
extraluminal tumor shows central necrosis (arrowhead) and reaches
the right pelvic wall
Fig. 7 Paraxial T2-weighted FSE (TSE) sequence of a low T4 rectal
cancer with infiltration of the levator ani muscle (arrow)
Fig. 6 a Paraxial T2-weighted
FSE (TSE) sequence and
b sagittal T2-weighted FSE
(TSE) sequence of a T4 cancer
located in the upper third of
the rectum invading the uterus
(arrows)
384relationship of the tumor to the mesorectal fascia,
representing the anticipated resection plane for TME in
order to assess the likelihood of a tumor-free CRM. Several
recent studies have confirmed that MRI is highly suited to
provide this information [54, 57–60]. In a study of 43
patients, Bissett et al. [59] found good agreement between
preoperative MRI and histopathology with regard to the
demonstration of tumor penetration through the mesorectal
fascia (accuracy: 95%). These results are underlined by the
studies of Beets-Tan et al. [54, 61], who investigated 76
patients and likewise found preoperative MRI to be highly
accurate in assessment of the CRM. The agreement was
100% in T4 tumors, and 97% and 93% for both readers in
tumors with a histologically determined tumor-free CRM
>10 mm. Regression analysis for histologically determined
margins of 1–10 mm demonstrated that a tumor-free
resection margin of 2 mm was predicted with an accuracy
of 97% if the distance between tumor and mesorectal fascia
measured by MRI was at least 6 mm. It is noteworthy that
this study likewise showed only moderate results with
regard to T-staging (accuracy of 83% and 67% for the two
readers) [54, 61]. In a study of 98 patients published by
Brown and co-workers in 2003, the agreement between
MRI and histology in assessment of the CRM was 92%
[60]. These figures indicate that MRI allows accurate
prediction of the CRM status after resection. The expected
CRM can be described as involved if tumor invasion of the
mesorectal fascia is visible or the tumor has a proximity of
1 mm or less to the mesorectal fascia. A tumor-free CRM
can be assumed with a high degree of accuracy if the
shortest distance from the maximum tumor extension, a
mesorectal tumor deposit or a suspect lymph node in the
mesorectum is more than 6 mm [54]. The role of tumors
that extend towards the mesorectal fascia to a distance of
less than 5 mm on MR images remains controversial.
The study by Brown et al. [60] also suggests that other
important prognostic factors besides the CRM are the
infiltration of extramural veins and possible infiltration of
the peritoneal fold and that these can also be identified by
preoperative MRI.
A study by Oberholzer and co-workers published in
2005 has shown that parallel imaging techniques do not
compromise diagnostic accuracy with regard to the
assessment of the CRM, but can considerable shorten the
examination [62].
N-staging
Identification of metastatic lymph nodes is the greatest
challenge in preoperative staging of rectal cancer, regard-
less of the modality used (Figs. 9, 10, 11). Exact staging is
important because the number of metastatic nodes has been
shown to affect the prognosis [63]. Involvement of lymph
nodes in the vicinity of the mesorectal fascia is associated
with a higher risk of local recurrence [16]. In patients with
metastatic nodes outside the mesorectal fascia, extended
lymph node resection with additional removal of the
internal iliac nodes becomes necessary [64]. This lymph
node group is not removed when regular TME is
performed. A special problem associated with identifying
lymphatic involvement in rectal cancer is that lymph node
size is not a reliable criterion for metastatic involvement
because micrometastasis in normal-sized lymph nodes is
common [65, 66].
Fig. 9 Sagittal T2-weighted FSE (TSE) sequence. The enlarged
mesorectal lymph node (arrow) shows heterogenous signal intensity
indicating tumor invasion
Fig. 10 Axial PD-weighted FSE (TSE) sequence. A large lymph
node metastasis (asterisk) located below the aortic bifurcation in a
patient with rectal cancer
385The accuracy rates reported in the literature for N-
staging by the different imaging modalities vary widely
(EUS: 61–80% [10, 25, 26, 30–32, 34, 35, 37, 67], CT: 56–
79% [32, 39, 68, 69], MRI: 57–85% [32, 39, 47, 53, 55,
60]. In a current meta-analysis including 84 studies,
Lahaye et al. [70] found EUS to be slightly superior in
assessing nodal status, but there were altogether no
significant differences between the three staging modalities
investigated. In summary, these results suggest that none of
the imaging procedures currently in use enables reliable
detection of metastatic lymph nodes.
In their study of MRI with histologic correlation, Brown
et al. [71] identified an irregular contour and inhomoge-
neous signal to be the most reliable MRI criteria for lymph
node metastasis (Fig. 9).
Future perspectives
USPIO
A new promising approach to detect metastatic lymph
nodes by MRI is imaging in combination with ultrasmall
superparamagnetic iron oxide particles (USPIO) as a
contrast medium for systemic MR lymphography
(Fig. 12a,b). Following intravenous administration, the
particles are phagocytozed by nodal macrophages and, due
to susceptibility effects, cause a signal decrease in normal
or reactively changed lymph nodes on T2- and T2*-
weighted images, which are usually acquired 24 h after
administration of USPIO [72]. USPIO agents are currently
under clinical evaluation and are not yet clinically
available. Initial results of a study investigating this new
approach in mesorectal lymph nodes are promising [73].
Further studies are needed to show whether USPIO can
significantly improve lymph node staging by MRI.
Whole-body MRI
The recent introduction of powerful whole-body MRI
systems enables imaging of the whole body in a single
session through repeated table movement. Several studies
have already demonstrated the benefit of this approach for
a variety of diagnostic queries in oncologic patients [74–
77]. This technique may also be used for rectal cancer
staging in the future and allow local staging and whole-
body staging in a single session. In this way it would
become possible to also evaluate the liver as the primary
target organ of hematogenic spread of rectal cancer. The
potential of parallel imaging to shorten the examination
Fig. 12 a Axial PD-weighted sequence of the pelvis. Two small
lymph nodes are visible adjacent to the iliac vessels (arrows).
b Axial T2*-weighted gradient echo sequence acquired 24 hours
after i.v. infusion of USPIO (Sinerem). The two lymph nodes
(arrows) show homogenous signal decrease indicating normal
lymphatic tissue. As USPIO agents are currently under clinical
evaluation and are not yet clinically available, this image was
acquired during a clinical trial
Fig. 11 Axial T2-weighted FSE (TSE) sequence. Inguinal lymph
node metastases (arrows) in a patient with low rectal cancer
386that has already been mentioned would be of particular
significance in this respect [62].
Diffusion/perfusion-weighted MRI and PET
It has long been known that the pathophysiology and
aggressiveness of a tumor are determined not only by the
macroscopic tumor extent but also by other factors such as
tumor microcirculation and angiogenesis. Several studies
have shown the potential of diffusion- or perfusion-
weighted imaging to indirectly determine these factors
and to thus predict the response to adjuvant or neoadjuvant
therapy [78–81]. However, extensive further research is
necessary before the routine clinical use of these new
techniques.
Recent studies have indicated that PET is able to predict
response to neoadjuvant treatment of locally advanced
rectal cancer with a high degree of accuracy [82].
Conclusion
The advances that have been made in the treatment of rectal
cancer in recent years and that have considerably improved
the prognosis of affected patients rely on differentiated
pretherapeutic tumor staging. Despite its known limitations
in T-staging, MRI is currently the only imaging modality
that enables highly accurate evaluation of the topographic
relationship between lateral tumor extent and the meso-
rectal fascia and to thus make a prediction about the CRM.
In this way it is possible to carefully select those patients
who will benefit from neoadjuvant therapy and to avoid
overtreatment or undertreatment.
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